2-ethyl-3-phenyl-4-(4-bromophenyloxy)-7-methoxyquinoline | 828300-18-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 2-ethyl-3-phenyl-4-(4-bromophenyloxy)-7-methoxyquinoline
• 英文别名: 4-(4-Bromophenoxy)-2-ethyl-7-methoxy-3-phenylquinoline
• CAS: 828300-18-1
• 化学式: C₂₄H₂₀BrNO₂
• 分子量: 434.332
• InChiKey: OMGLQKWNAJGXEF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.8
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  31.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-ethyl-3-phenyl-4-(4-bromophenyloxy)-7-methoxyquinoline 在 palladium diacetate 、 三溴化硼 、 三乙胺 、 三苯基膦 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 生成 (E)-3-[4-(2-ethyl-7-hydroxy-3-phenylquinolin-4-yl)oxyphenyl]-1-piperidin-1-ylprop-2-en-1-one
  参考文献：
  名称：

  Discovery of Novel Quinoline-Based Estrogen Receptor Ligands Using Peptide Interaction Profiling

  摘要：

  Traditional approaches to discovery of selective estrogen receptor modulators (SERMs) have relied on ER binding and cell-based estrogen response element-driven assays to identify compounds that are osteoprotective but nonproliferative in breast and uterine tissues. To discover new classes of potential SERMs, we have employed a cell-free microsphere-based binding assay to rapidly characterize ER alpha interactions with conformation-sensing cofactor or phage display peptides. Peptide profiles of constrained triarenes were compared to known proliferative and nonproliferative ER ligands to discover potent quinoline-based ligands with minimal Ishikawa cell stimulation.

  DOI：

  10.1021/jm040154f
• 作为产物：
  描述：

  4-羟基-7-甲氧基-3-苯基喹啉-2(1H)-酮 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 sodium hydroxide 、 potassium carbonate 、 三氯氧磷 作用下， 以 四氢呋喃 、 正己烷 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 32.0h， 生成 2-ethyl-3-phenyl-4-(4-bromophenyloxy)-7-methoxyquinoline
  参考文献：
  名称：

  Discovery of Novel Quinoline-Based Estrogen Receptor Ligands Using Peptide Interaction Profiling

  摘要：

  Traditional approaches to discovery of selective estrogen receptor modulators (SERMs) have relied on ER binding and cell-based estrogen response element-driven assays to identify compounds that are osteoprotective but nonproliferative in breast and uterine tissues. To discover new classes of potential SERMs, we have employed a cell-free microsphere-based binding assay to rapidly characterize ER alpha interactions with conformation-sensing cofactor or phage display peptides. Peptide profiles of constrained triarenes were compared to known proliferative and nonproliferative ER ligands to discover potent quinoline-based ligands with minimal Ishikawa cell stimulation.

  DOI：

  10.1021/jm040154f

文献信息

• [EN] SUBSTITUTED QUINOLINE COMPOUNDS FOR USE AS SELECTIVE ESTROGEN RECEPTOR MODULATOR<br/>[FR] COMPOSES QUINOLEINE SUBSTITUES A UTILISER EN TANT QUE MODULATEURS SELECTIFS DU RECEPTEUR DES OESTROGENES
  申请人：SMITHKLINE BEECHAM CORP

  公开号：WO2005082857A1

  公开（公告）日：2005-09-09

  The present invention relates to novel compounds of Formula (I) with a variety of therapeutic uses, more particularly novel substituted quinoline compounds particularly useful for selective estrogen receptor modulation.

  本发明涉及具有多种治疗用途的新型化合物（I）的配方，更具体地说是特别适用于选择性雌激素受体调节的新型取代喹啉化合物。
• Substituted Quinoline Compounds For Use As Selective Estrogen Receptor Modulator
  申请人：Hoekstra Joel William

  公开号：US20070203180A1

  公开（公告）日：2007-08-30

  The present invention relates to novel compounds of formula (I) with a variety of therapeutic uses, more particularly novel substituted quinoline compounds particularly useful for selective estrogen receptor modulation.

  本发明涉及公式(I)的新化合物，具有多种治疗用途，更特别地，是新的取代喹啉化合物，特别适用于选择性雌激素受体调节。
• US7405303B2
  申请人：——

  公开号：US7405303B2

  公开（公告）日：2008-07-29